Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07672262 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

VA Consolidation in Intermediate-Risk AML

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
This clinical trial aims to compare the efficacy and safety of venetoclax-based consolidation therapy versus conventional consolidation chemotherapy (intermediate/high-dose cytarabine) in newly diagnosed adult patients with intermediate-risk acute myeloid leukemia (AML). Participants must have achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) after induction therapy with venetoclax and azacitidine and are planned to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Trial Details
NCT Number NCT07672262
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions
(from sponsor)		 Acute Myeloid Leukemia, Intermediate Risk Acute Myeloid Leukemia, Consolidation Therapy
Related terms Leukemia, Myeloid, Acute
Enrollment 226 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov